Arabinofuranosylcytosine Triphosphate
"Arabinofuranosylcytosine Triphosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A triphosphate nucleotide analog which is the biologically active form of CYTARABINE. It inhibits nuclear DNA synthesis.
| Descriptor ID |
D001085
|
| MeSH Number(s) |
D03.383.742.686.246.050 D13.695.065.200 D13.695.740.246.050
|
| Concept/Terms |
Arabinofuranosylcytosine Triphosphate- Arabinofuranosylcytosine Triphosphate
- Triphosphate, Arabinofuranosylcytosine
- Cytosine Arabinoside Triphosphate
- Triphosphate, Cytosine Arabinoside
- Cytarabine Triphosphate
- Triphosphate, Cytarabine
- Ara-CTP
- Ara CTP
- Arabinosylcytosine Triphosphate
- Triphosphate, Arabinosylcytosine
|
Below are MeSH descriptors whose meaning is more general than "Arabinofuranosylcytosine Triphosphate".
Below are MeSH descriptors whose meaning is more specific than "Arabinofuranosylcytosine Triphosphate".
This graph shows the total number of publications written about "Arabinofuranosylcytosine Triphosphate" by people in this website by year, and whether "Arabinofuranosylcytosine Triphosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 2 | 3 |
| 1996 | 0 | 4 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Arabinofuranosylcytosine Triphosphate" by people in Profiles.
-
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007 Dec; 323(3):935-45.
-
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002 Oct 15; 20(20):4217-24.
-
Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin Cancer Res. 1998 Jul; 4(7):1719-26.
-
Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep; 3(9):1539-45.
-
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9.
-
Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki. 1996 May; 37(5):369-79.
-
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996 Apr; 2(4):653-8.
-
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 01; 87(1):256-64.
-
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8.
-
Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994; 34(1):30-6.